Open Label Clinical Trial of Intravenous Crotoxin Part 3
Starting soon · Phase 1
Conditions studied: Cancer
In brief
The primary objective of the study is to assess whether human subjects can be made tolerant to intravenously administered Crotoxin and achieve higher and more therapeutically effective doses levels without the previously reported adverse effects associated with bolus i.m. administration.
Key facts
- Study ID
- NCT01481532
- Run by
- Celtic Biotech Ltd
- People needed
- 24
- Starts
- 2026-10-01
- Expected to finish
- 2027-11-01
- Last updated by the study team
- 2026-04-15
Who can join
Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Institut de Cancérologie de l'Ouest — Saint-Herblain, France
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.